BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180925
DTEND;VALUE=DATE:20180928
DTSTAMP:20260515T041946
CREATED:20180808T115442Z
LAST-MODIFIED:20180808T115700Z
UID:17070-1537833600-1538092799@www.pharmajournalist.com
SUMMARY:IMPACCT: RWE - Real-World Evidence Conference 2018
DESCRIPTION:IMPACCT: RWE is taking place in Boston\, MA on September 25-27 2018\, and is the only meeting dedicated to supporting drug developers in making real-world evidence-based decisions\, from clinical development to commercialization of their products. \n\nAttend this meeting and benefit from: \n\nCase-Study Led Content\nWe know the value of case-study led discussions. That’s why at the IMPACCT:RWE Summit we’ve tailor-made an agenda that contains over eighteen case studies around how real-world evidence is currently being applied across the drug development continuum to support decision-making in clinical development\, drug marketing and commercialization\, and how you can define and develop a comprehensive evidence generation plan that supports activities from clinical to commercial. You will have a chance to discuss with peers and learn from thought leaders in the industry such as Lundbeck\, Biogen\, BMS\, Amgen\, GSK\, Pfizer and more.\nMeet and Network with Industry Pioneers\nWith a room full of senior drug development and commercialization professionals striving to effectively leverage real-world evidence to benefit patients\, this summit is your chance to meet like-minded industry peers to shape the future of RWE together.\nPre-Conference Workshop Session\nIn a highly engaging and interactive discussion\, you will learn decision science basics\, including implementation examples. The group will also explore opportunities and strategies for RWE to leverage decision science as a vehicle to achieve greater value by informing and helping to change drug development and commercial decision making within your organization.\n\nTo learn more about this event\, visit http://bit.ly/2OP3kMW
URL:https://www.pharmajournalist.com/event/impacct-rwe-real-world-evidence-conference-2018/
LOCATION:Hilton Boston/Woburn\, 2 Forbes Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:mafalda.andrade@impacct-rwe.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180926
DTEND;VALUE=DATE:20180928
DTSTAMP:20260515T041946
CREATED:20180411T161558Z
LAST-MODIFIED:20180411T161558Z
UID:14392-1537920000-1538092799@www.pharmajournalist.com
SUMMARY:Biosimilars & Biobetters 2018
DESCRIPTION:SMi presents the 9th Annual Conference on Biosimilars & Biobetters\nForecasting the next wave of biosimilars to ensure optimal market commercialisation \nThe SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters\, taking place on 26th & 27th September in Central London\, UK. Following the success of our previous events in both London and the US\, Biosimilars and Biobetters UK 2018 will deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market. \n\nAfter over a decade\, the biosimilars industry is finally reaching a stage where key stakeholders understand and accept biosimilars. This is reflected in more tolerant legislation and an increased uptake of biosimilars across the globe. \nWe are now entering a very exciting time\, for over the next few years several originator patents are expiring\, and we will see the next few waves of biosimilars enter the market. Will the biosimilar be a successful contender and spark a competitive environment or the originator dominate? Have we done enough to convince the payer\, prescriber and patient to switch? \nJoin us to hear experiences of key opinion leaders and evaluate market access\, opportunities and commercialisation strategies with industry-thought experts. \nThis event is CPD accredited. \n#SMiBiosimilars \nWHO SHOULD ATTEND \nChief Executives\, Vice Presidents\, Executive Directors\, Directors\, Heads\, Managers and Specialists from the following\, but not limited to\, sectors should attend: \n\nBiosimilars / Biologics\nBiopharmaceuticals\nResearch and Development\nLegal Affairs\nIntellectual Property\nRegulatory Compliance\nQuality affairs and control\nPharmacovigilance\, Drug Safety and Risk Management\nBusiness Development\nCommercialisation\nMarketing and sales\n\nEARLY BIRD-RATES \n\nBOOK BY 30TH APRIL AND SAVE £400\nBOOK BY 31ST MAY AND SAVE £200\nBOOK BY 29TH JUNE AND SAVE £100\n\nTo learn more about this event\, and to register online\, visit http://www.biosimilars-europe.com/pharmajournalistWL
URL:https://www.pharmajournalist.com/event/biosimilars-biobetters-2018/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180926
DTEND;VALUE=DATE:20180928
DTSTAMP:20260515T041946
CREATED:20180501T144153Z
LAST-MODIFIED:20180501T144153Z
UID:15510-1537920000-1538092799@www.pharmajournalist.com
SUMMARY:Immuno-Oncology
DESCRIPTION:Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. \nSMi’s Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry\, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress. \n\nAt the SMi’s Immuno-Oncology Conference participants will get: \nAgenda-  Over 15 engaging presentations\, case studies\, keynote addresses\, including: \n\nTargeting immune checkpoints with Humabody VH therapeutics\nRecent advances in providing durable disease control with Keytruda as an anti-cancer therapy\nTumour mutation burden and the potential of its use as an indication of treatment choice\nUnwanted immunogenicity and functionality testing of immuno-oncology drugs\nNew techniques\, such as the emerging applications of liquid biopsies\, in Immuno-Oncology\n\nSpeakers–Over 15 leading experts in Immuno-Oncology field\, including: \n\nJames Legg\, Vice President R&D\, Crescendo Biologics\nAndrew Exley\, Medical Assessor\, MHRA\nHarry Smith\, Medical Scientist\, Gilead Sciences\nGrace Macaulay\, Global Safety Physician Patient Safety Oncology\, MedImmune\nDavid Giljohan\, CEO\, Exicure\nKandeepan Ganeshalingam\, Executive Director\, Oncology Therapeutic Area Head\, European Clinical Development\, MSD\nRochana Wickramasinghe\, Director of Oncology Evaluation\, AstraZeneca\n\nWorkshops – Carefully selected topics for further on-sight training. 2 pre-conference workshops (25 September) to provide in-depth knowledge on specific topics: \n\nStrategic Competitive Intelligence in the Immuno-Oncology space – hosted by LucidQuest Ventures\nCould the Microbiome boost Cancer Immuno-Therapy – hosted by ImmuneBiotech and Lund University\n\nNetworking – it is at the forefront of SMi events. 5+ hours of pure networking guaranteed. Follow event updates to be in the know about who will be joining the conversation. \nTo View detailed information about event programme\, speaker line-up and workshop agenda visit http://www.immuno-oncology-conference.com/phjWL \nTwitter – @SMIpharm & #immunooncologysmi \nLinkedIn – SMi Pharma
URL:https://www.pharmajournalist.com/event/immuno-oncology/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:durneva@smi-online.co.uk
END:VEVENT
END:VCALENDAR